Table 3 Information of the five most popular WeChat official accounts (from August 16, 2017 to August 16, 2018)
Official WeChat accounts | CCCF | IBD in Love | The IBD team of Sir run run Shaw hospital | IBD Academic Officer | The World of Gastroenterology |
|---|---|---|---|---|---|
Organization | The China Crohn’s & Colitis Foundation | The 6th hospital of Sun Yat-sen university | Sir run run Shaw hospital of Zhejiang University | Technology company and medicine related person | Technology company and medicine related person |
Duration since setting up | 55 months | 47 months | 46 months | 16 months | 48 months |
Total number of articles | 260 | 124 | 59 | 393 | 147 |
Update frequency (days) a | 1.40 | 2.94 | 6.19 | 0.93 | 2.48 |
Average reading number for each article | 1479 ± 1174 | 1176 ± 1060 | 1419 ± 849 | 1092 ± 665 | 1110 ± 880 |
Highest reading number | 10,810 | 4885 | 5626 | 6084 | 4234 |
Comments | 6.51 ± 10.38 | 1.60 ± 3.58 | 1.49 ± 5.41 | 1.41 ± 1.92 | 0.32 ± 1.06 |
Likes | 23.07 ± 20.85 | 13.90 ± 12.36 | 24.60 ± 31.00 | 12.58 ± 7.12 | 6.38 ± 6.82 |
Focus on CD | 249 (96%) | 106 (85%) | 57 (97%) | 346 (88%) | 115 (78%) |
Topic types [number (percentage%)] | |||||
1.Notices in diet and daily life | 20 (8%) | 12 (10%) | 4 (7%) | 13 (3%) | 8 (5%) |
2.General disease introduction | 28 (11%) | 4 (3%) | 7 (12%) | 85 (22%) | 77 (52%) |
3.Medication advances and side effects | 10 (4%) | 11 (9%) | 5 (8%) | 109 (28%) | 11 (7%) |
4.The prognosis and influencing factors | 9 (3%) | 6 (5%) | 4 (7%) | 70 (18%) | 7 (5%) |
5.Policy about subsidies and discounts for treatment | 0 (0%) | 1 (0.8%) | 1 (2%) | 3 (0.8%) | 0 (0%) |
6.Relevant knowledge about surgery | 7 (3%) | 3 (2%) | 4 (7%) | 29 (7%) | 6 (4%)) |
7.Communication with other patients | 20 (8%) | 15 (12%) | 0 (0%) | 0 (0%) | 0 (0%) |
8.Stories about defeating the disease | 13 (5%) | 6 (5%) | 8 (14%) | 0 (0%) | 0 (0%) |
9.Consensus and research | 54 (21%) | 17 (14%) | 4 (7%) | 66 (17%) | 38 (26%) |
10.Education activities for patients | 80 (31%) | 32 (26%) | 12 (20%) | 7 (2%) | 0 (0%) |
11.Clinical guidance | 5 (2%) | 6 (5%) | 9 (15%) | 1 (0.3%) | 0 (0%) |
12.Others | 7 (3%) | 4 (3%) | 0 (0%) | 3 (1%) | 0 (0%) |
Kappa value b | −0.143 | 0.143 | 0.286 | 0.259 | 0.000 |